{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.39","upperLimit":"9.43","value":"6.60"},{"comment":"The 95% CI was not available due to insufficient numbers of participants with events.","groupId":"OG001","lowerLimit":"5.78","upperLimit":"NA","value":"8.84"},{"comment":"The 95% CI was not available due to insufficient numbers of participants with events.","groupId":"OG002","lowerLimit":"2.79","upperLimit":"NA","value":"3.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"PFS 2 was defined as the duration of time from the date of the first dose of the treatment after SVd/Vd/SVdX until the first date of PD on treatment after SVd/Vd/SVdX or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \\>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; c) urine M-protein (absolute increase must be \\>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \\[\\>\\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \\>=10%).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a fixed oral dose of 100 milligrams (mg) selinexor tablets (5 tablets of 20 mg each) once weekly (QW) on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with subcutaneous (SC) injection of 1.3 milligrams per square meter (mg/m\\^2) bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone twice weekly (BIW) on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"OG000","title":"SVd Arm: Selinexor + Bortezomib + Dexamethasone"},{"description":"Participants who did not cross over were included and received SC injection of 1.3 mg/m\\^2 bortezomib on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by \\>= 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles \\>= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"OG001","title":"Vd Arm (Non-Crossover): Bortezomib + Dexamethasone"},{"description":"Participants in the VD arm who had IRC-confirmed PD and were able to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m\\^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"OG002","title":"SVdX Arm: Selinexor + Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"The ITT population consisted of all patients who were randomized to the study treatment, regardless of whether or not they received the study treatment. Here, \"Overall number of participants analyzed\" signifies those participants who were evaluable for this outcome measure. Data was not planned to be reported for Sdx arm.","reportingStatus":"POSTED","timeFrame":"From date of first dose of post-SVd/Vd/SVdX treatment to the date of first PD on post-SVd/Vd/SVdX treatment, or death due to any cause (up to 33 months)","title":"SVd/Vd/SVdx Arm: Progression Free Survival 2 (PFS 2) in Participants Randomized to the SVd and Vd Arm Who Received Post-SVd/Vd/SVdX Treatment","type":"SECONDARY","unitOfMeasure":"Months"}